The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

AAV8-hCocH for Cocaine Use Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04884594
Recruitment Status : Recruiting
First Posted : May 13, 2021
Last Update Posted : November 2, 2023
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
W. Michael Hooten, Mayo Clinic

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to test the safety of a novel gene viral vector treatment for adults with cocaine use disorder-sustained remission. This gene regulates an enzyme (cocaine hydrolase) that breaks down cocaine into inactive substances, thereby decreasing the pleasurable feeling this drug usually provides.

Condition or disease Intervention/treatment Phase
Cocaine Dependence, in Remission Drug: AAV8-hCocH Phase 1

Detailed Description:
This is a phase-I dose escalation clinical trial testing the safety and MTD of IV administration of AAV8-hCocH to subjects with a history of cocaine use disorder-sustained remission. Subjects who provide written informed consent, meet entry criteria, and do not have transduction inhibition to AAV8 (pre-existing AAV8 antibodies) will be eligible. Subjects will be enrolled sequentially every 2-3 months or longer between cohorts. Dose escalation may be initiated after a single subject has been safely dosed; maximum enzyme expression is anticipated at week 3-4. This escalation paradigm is intended to minimize the number of subjects exposed to sub-therapeutic doses. The starting dose is based on the expression and safety of AAV8-CocH in mice, rats and NHP, and previous human experience using AAV8-FVIII IV in hemophilia patients. The starting dose has a large safety margin (15-fold) from the NOAEL in NHP. Approximately 7 weeks after an injection, a decision to escalate to the next dose level will be made based on a review of safety parameters and CocH levels by the investigative team.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Intravenous Administration of AAV8-human Cocaine Hydrolase to Treat Cocaine Use Disorder
Actual Study Start Date : October 8, 2021
Estimated Primary Completion Date : December 2026
Estimated Study Completion Date : December 2026
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: AAV8-hCocH Low dose: 2e12 vg/kg
Cohort 1: Participant receives one-time IV administration of low dose 2e12 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
 Drug: AAV8-hCocH
2e12 vg/kg single infusion intravenous
Experimental: AAV8-hCocH Medium dose: 6e12vg/kg
Cohort 2: Participant receives one-time IV administration of medium dose 6e12vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
 Drug: AAV8-hCocH
6e12vg/kg single infusion intravenous
Experimental: AAV8-hCocH High dose: 2e13 vg/kg
Cohort 3: Participant receives one-time IV administration of high dose 2e13 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
 Drug: AAV8-hCocH
2e13 vg/kg single infusion intravenous


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Adverse Events [ Time Frame: 60 months ]
    Number of participants with treatment-related adverse events

  2. Change in enzyme expression profile [ Time Frame: Baseline, 24 months ]
    Serum level of AAV8-hCocH gene expression


Secondary Outcome Measures :
  1. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: 24 months ]
    Cmax is measured as the peak concentration of AAV8 in the blood after intravenous infusion

  2. Time of peak concentration (tmax) [ Time Frame: 24 months ]
    The time to maximum plasma concentration of AAV8 in the blood after intravenous infusion

  3. Half-Life (t1/2) [ Time Frame: 24 months ]
    The time for plasma concentration of AAV8 in the blood to be reduced to exactly half of starting concentration

  4. Area under the Concentration-Time Curve (AUC) [ Time Frame: 24 months ]
    AUC is a measure of the AAV8 serum concentration over time. Used to characterize drug absorption.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non-treatment seeking male or females ages 18 to 65 years, inclusive.
  • DSM-5 diagnosis of cocaine use disorder in sustained remission as confirmed by the PI's review of the medical record.
  • Are motivated to abstain from cocaine use during the period of the study, as evidenced both by the judgment of the Investigator or designee and by compliance with the requirement to make regular clinic visits.
  • In the opinion of the PI, be in good general health as determined by medical and psychiatric history, general clinical examination, vital signs, and laboratory tests.
  • Have provided written informed consent. Subjects should be cooperative, willing and able to participate and adhere to the protocol requirements.
  • Have hematology, chemistry, kidney and liver function laboratory tests that are within (+/- 10%) of the current Mayo Clinic standardized normal values.
  • Show a baseline EKG that demonstrates normal sinus rhythm and conduction without clinically significant abnormalities or arrhythmias.
  • Are willing to return to research area for follow-up.

Exclusion Criteria:

  • They show detectable pre-existing immunity to the AAV8 capsid as measured by AAV8 transduction inhibition and AAV8 total antibodies.
  • Evidence of HIV or hepatitis of any etiology.
  • Creatinine ≥ 1.5 mg/dL.
  • Any disease or mental health condition at the physician's discretion that would prevent the subject from fully complying with the requirements of the study. The physician may exclude subjects with active alcohol abuse, other substance abuse or positive urine toxicology screen for substances of abuse.
  • Pregnant &/or lactating. All lactating women will be excluded from study participation. Women of child-bearing potential must have a negative pregnancy test performed at screening visit, agree to use birth control throughout the study period, refrain from getting pregnant within the study period and consent to pregnancy testing throughout the study period. Men must agree to use barrier methods of birth control and refrain from fathering children within the next year.
  • Morbid obesity (BMI > 40).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04884594


Contacts
Layout table for location contacts
Contact: Brenda Anderson, RN (507) 255-7157 Hooten.william@mayo.edu

Locations
Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester Recruiting
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
W. Michael Hooten
National Institute on Drug Abuse (NIDA)
Investigators
Layout table for investigator information
Principal Investigator: W. Michael Hooten, MD Mayo Clinic
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: W. Michael Hooten, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT04884594    
Other Study ID Numbers: 20-012225
5UH3DA042492 ( U.S. NIH Grant/Contract )
First Posted: May 13, 2021    Key Record Dates
Last Update Posted: November 2, 2023
Last Verified: October 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders